Patents by Inventor Alan Wellington Faull

Alan Wellington Faull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120289513
    Abstract: The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.
    Type: Application
    Filed: July 25, 2012
    Publication date: November 15, 2012
    Applicant: ASTRAZENECA AB
    Inventors: John Cumming, Alan Wellington Faull, David Waterson
  • Publication number: 20100152197
    Abstract: The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.
    Type: Application
    Filed: December 10, 2009
    Publication date: June 17, 2010
    Applicant: ASTRAZENECA AB
    Inventors: John Cumming, Alan Wellington Faull, David Waterson
  • Publication number: 20100099708
    Abstract: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)?iperidin-4-yl]propyl}piperidine formula (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: April 22, 2010
    Inventors: Alan Wellington Faull, Steven Swallow
  • Publication number: 20100093795
    Abstract: The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine formula (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: April 15, 2010
    Inventors: Dearg Sutherland Brown, Alan Wellington Faull, Steven Swallow
  • Publication number: 20100029754
    Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 7, 2009
    Publication date: February 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Alan Wellington Faull, Craig Johnstone, Andrew David Morley, Jeffrey Philip Poyser
  • Patent number: 7572826
    Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: August 11, 2009
    Assignee: AstraZeneca AB
    Inventors: Alan Wellington Faull, Craig Johnstone, Andrew David Morley, Jeffrey Philip Poyser
  • Publication number: 20080139613
    Abstract: The present invention relates to 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine (I): or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 12, 2008
    Applicant: AstraZeneca AB
    Inventors: Dearg Sutherland Brown, Alan Wellington Faull, Steven Swallow
  • Publication number: 20080139612
    Abstract: The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 12, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Alan Wellington Faull, Steven Swallow
  • Patent number: 6984657
    Abstract: A compound of Formula I, wherein: R1 is hydrogen, halo, methyl, ethyl or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, trifluoromethyl, nitro, cyano, trifluoromethoxy, C(O)R7, or S(O)nR7 where n is 0, 1 or 2 and R7 is an alkyl group; R4 is a halo, trifluoromethyl, methylthio, methoxy, trifluoromethoxy or lower alkyl, lower alkenyl or lower alkynyl or COR8 where R8 is lower alkyl; R6 is hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl or COR9 where R9 is lower alkyl; provided that when R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy, R5 and R6 are both hydrogen, and one of R3 or R4 is not halo or trifluoromethyl; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonizing an MCP-1 mediated effect in a warm-blooded animal such as a human being.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: January 10, 2006
    Assignee: AstraZeneca AB
    Inventors: Alan Wellington Faull, Jason Grant Kettle
  • Patent number: 6953809
    Abstract: The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: October 11, 2005
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Patent number: 6730672
    Abstract: The invention concerns compounds of formula (I) wherein each of G1, G2 and G3 is CH or N; m is 1 or 2; R1 includes hydrogen, halogeno and (1-4C)alkyl; M1 is a group of the formula: NR2—L1—T1R3 in which R2 and R3 together form a (1-4C)alkylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2R4)r—L2—T3R5 in which r is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: May 4, 2004
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
  • Publication number: 20030144339
    Abstract: A compound of formula (I) wherein: R1 is hydrogen, halo or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group or a trifluoromethyl group; R4 is a halo group or a trifluoromethyl group; R5 is hydrogen or halo; R6 is hydrogen or halo; provided that when R5 and R6 are both hydrogen, and one of R3 or R4 is chloro or fluoro, then the other is not chloro or fluoro; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonising an MCP-1 mediated effect in a warm-blooded animal such as a human being.
    Type: Application
    Filed: July 9, 2002
    Publication date: July 31, 2003
    Inventors: Alan Wellington Faull, Jason Grant Kettle
  • Publication number: 20030119830
    Abstract: The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
    Type: Application
    Filed: July 15, 2002
    Publication date: June 26, 2003
    Applicant: ZENECA LIMITED
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Publication number: 20020119968
    Abstract: The invention concerns compounds of formula (I) 1
    Type: Application
    Filed: March 8, 2001
    Publication date: August 29, 2002
    Applicant: ZENECA LIMITED
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
  • Patent number: 6441004
    Abstract: The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: August 27, 2002
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Patent number: 6288103
    Abstract: The invention concerns pharmaceutically useful indoles of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, as well as pharmaceutical compositions containing them. The novel compounds possess inhibitory activity against monocyte chemoattractant protein-1 (MCP-1). The invention further concerns the use of such indoles in the treatment of a disease or condition mediated by MCP-1.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: September 11, 2001
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Patent number: 6225309
    Abstract: The invention concerns compounds of formula (I), wherein each of G1, G2 and G3 is CH or N; m is 1 or 2; R1 includes hydrogen, halogeno and 1-C)alkyl; M1 is a group of formula: NR2—L1—T1R3, in which R2 and R3 together form a (1-4C)alylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2R4)rL2—T3R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.
    Type: Grant
    Filed: August 9, 1999
    Date of Patent: May 1, 2001
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
  • Patent number: 6022869
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties; processes for preparing compounds of formula (I) and pharmaceutical compositions.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: February 8, 2000
    Assignee: Zeneca Limited
    Inventor: Alan Wellington Faull
  • Patent number: 5981531
    Abstract: The invention concerns acid derivatives of formula IR.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --Gand pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: November 9, 1999
    Assignee: Zeneca Limited
    Inventors: Andrew George Brewster, Peter William Rodney Caulkett, Alan Wellington Faull, Robert James Pearce, Richard Eden Shute
  • Patent number: 5965559
    Abstract: The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: October 12, 1999
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston